European Regulatory Committee Recommends Orphan Drug Status for GPC Biotech's Anticancer Monoclonal Antibody
GPC Biotech AG announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) has recommended the granting of orphan medicinal product designation for the anticancer monoclonal antibody 1D09C3 for the treatment of multiple myeloma. The orphan drug status becomes effective when the European Commission has approved this recommendation. 1D09C3 is currently in a Phase 1 clinical program that is evaluating the antibody in patients with relapsed or refractory B-cell lymphomas, including Hodgkin's and non-Hodgkin's lymphomas, who have failed prior standard therapy.
1D09C3 is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. 1D09C3 binds to MHC class II molecules on the cell surface and in preclinical studies appears to selectively kill activated, proliferating tumor cells, which include B-cell and T-cell lymphomas. In preclinical studies, 1D09C3 has been shown to induce programmed cell death and does not require a functioning immune system for its cell-killing effect. A Phase 1 clinical program evaluating 1D09C3 in patients with relapsed or refractory B-cell lymphomas who have failed prior standard therapy, is currently underway at several major cancer centers in Europe. 1D09C3 has been granted orphan medicinal product designation for the treatment of Hodgkin's lymphoma and chronic lymphocytic leukemia.
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

More efficient biosolar cells modelled on nature - By combining light-collecting and photosynthesis proteins of different types, more energy can be produced

Artificial enzymes convert solar energy into hydrogen gas
A vaccine alternative protects mice against malaria - Vectored immunoprophylaxis injection triggers creation of antibodies that prevent malaria in 70 percent of mice

KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform - AstriVax to develop novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection

Occludin protein plays key role in spread of coronavirus throughout body’s cells - Finding gives insight into how the virus spreads throughout the human body, may help development of antiviral drugs
Merck strengthens biorefineries of the future

More Brain Lesions in Senior Women than in Men of the Same Age - The Extent of Abnormalities in the Brain’s White Matter Grows Significantly After Menopause

Gene found to be crucial for formation of certain brain circuitry - Identified using new technique that can speed identification of genes, drug candidates
Affibody and Agilent Technologies to Develop Robust Protein Sample

The pangenome - key to new therapies - Genetic diversity opens up new ways to treat life-threatening diseases

New base at the heart of science and industry - LUMITOS AG now calls Germany's largest science and technology park in Berlin-Adlershof its home
